The effect of incentive-based formularies on prescription-drug utilization and spending.
about
Pharmaceutical policies: effects of cap and co-payment on rational drug useThe new medicare drug benefit: formularies and their potential effects on access to medicationsThe effects of the coverage gap on drug spending: a closer look at Medicare Part DThe experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine useChanges in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gapA blueprint for pharmacy benefit managers to increase valuePotential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription DrugsMedicare prescription drug coverage: consumer information and preferences.N-of-1 trials of expensive biological therapies: a third way?Pharmacists' views and reported practices in relation to a new generic drug substitution policy in Lebanon: a mixed methods study.Specification Issues in a Big Data Context: Controlling for the Endogeneity of Consumer and Provider Behaviours in Healthcare Treatment Effects Models.Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007Preferred drug lists: potential impact on healthcare economics.Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.Systematic review on quality control for drug management programs: is quality reported in the literature?Medicare part d and the federal employees health benefits program: a comparison of prescription drug coverage.Reference drug programs: effectiveness and policy implications.The impact of cost sharing on antidepressant use among older adults in British Columbia.Comparison of tiered formularies and reference pricing policies: a systematic review.Sensitivity of medication use to formulary controls in medicare beneficiaries: a review of the literature.Increased Patient Cost-Sharing, Weak US Economy, and Poor Health Habits: Implications for Employers and Insurers.Expect the unexpected: a role for behavioral economics in understanding the impact of cost-sharing on emergency department utilization.Trends in pharmaceutical expenditures: the impact on drug benefit designAdherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarctionEffects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications.Medication adherence and use of generic drug therapies.Impact of medicare part D plan features on use of generic drugs.Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritisConsumer-directed health care: will it improve health system performance?Pharmaceutical cost management and access to psychotropic drugs: the U.S. contextImpact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.The impact of Medicare Part D on medication treatment of hypertension.From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.The effect of pharmacy benefit design on patient-physician communication about costsPrinciples for evidence-based drug formulary policy.How do quality information and cost affect patient choice of provider in a tiered network setting? Results from a survey.Beliefs about generic drugs among elderly adults in hospital-based primary care practicesIncreasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment.Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease.
P2860
Q24242490-FCAB910C-ED0E-4D5B-9D0C-BA39EFA93075Q24540426-DDB68D33-56B4-4D3D-A7DA-1B29A4BCA5EEQ24632713-62661E4D-8239-47E0-AEDB-5115FCA57B12Q27007695-031028A4-AA45-4BA4-956B-572608A11A2CQ28476575-FFA2332D-350A-41FE-B207-A71DE07EFCD1Q28766235-3BDD7742-7151-4DFE-9A7D-FF9E87ADA8B8Q29393270-E69E5E0C-5971-4B67-8C42-6F8EF36D791AQ30477378-98B4AC49-77E1-4146-A0DB-B567A043DA6BQ30483827-B0F3163C-866A-4452-B416-C5E2FE3A4E55Q30839146-9FC5F52D-C6DC-405B-8C7F-01F2B0FD1750Q31033194-A8E0F84C-A40C-498C-8B04-740748426FACQ33327179-1CD6E24D-B101-425C-93EF-7B4F1BB5FF04Q33344612-BE382A95-CE55-4058-9CBA-08B5B8BE18D0Q33404862-4241B06B-373A-40C1-9D30-9D11F7EED1C2Q33412577-9C4D8FC8-3DAF-4091-B548-67FC48C08E26Q33652790-E0528B18-D802-4578-A5CA-91B162CB652AQ33908085-A64AE597-5043-4816-A92D-619556238928Q33908092-505CABEE-50BC-40BB-9DEF-FA3AFF5E43DDQ33908282-36E66EE8-62D8-4107-9B60-34D3483E9532Q33931960-7FB331D7-5EEE-42F3-9B65-C25A6BE20C49Q33932255-D0E5D9A1-B144-4D49-980D-727E960C8AFCQ33932381-DAFF3613-B000-40F9-951F-42DE3F9900CBQ33932532-8487705A-A527-4A14-BF9C-8ABE13CD4E6FQ34001855-CA574F19-2CF7-4434-B39A-1D66A2D973B5Q34001878-1187B019-46EA-4524-AFD0-65B5D36264ACQ34001895-F895AA36-3EC3-40F1-BC72-9539B406D34CQ34052798-CEF3568B-9381-43F2-B062-E4EA70D12208Q34079971-4DFE1407-7719-480A-91F2-3510D816D996Q34248283-CDF93939-3011-42B9-9D5D-C8474E5F1CDDQ34336714-C6513436-6FBA-40D1-AD90-2F2021EA62CAQ34390982-BAB75094-6D23-4FB4-8876-33F28484109FQ34452710-F6219CC7-C122-42D9-BB41-022F2507D736Q34554697-C1A22036-5AE7-451F-8141-A6DAF423F72EQ34613417-4FADB123-3FE3-435D-924F-81C78075AA80Q34704557-7CAF6444-E46B-448D-996C-E9C8F8D2CEC4Q34724227-5B4EDEFC-B38D-423D-970F-20621FA4E622Q34724735-B276C942-2510-4723-8D90-D813FD8B82B1Q34809382-85B7DC9B-1560-484E-B426-4CE49FBFA868Q34927764-B43AEA6C-386A-4A17-8285-B99B661162E6Q35131284-E18F8F13-5F16-43CC-9BA1-DD238085E990
P2860
The effect of incentive-based formularies on prescription-drug utilization and spending.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The effect of incentive-based formularies on prescription-drug utilization and spending.
@ast
The effect of incentive-based formularies on prescription-drug utilization and spending.
@en
type
label
The effect of incentive-based formularies on prescription-drug utilization and spending.
@ast
The effect of incentive-based formularies on prescription-drug utilization and spending.
@en
prefLabel
The effect of incentive-based formularies on prescription-drug utilization and spending.
@ast
The effect of incentive-based formularies on prescription-drug utilization and spending.
@en
P2093
P356
P1476
The effect of incentive-based formularies on prescription-drug utilization and spending.
@en
P2093
Arnold M Epstein
Haiden A Huskamp
Kimberly A McGuigan
Patricia A Deverka
Richard G Frank
Robert S Epstein
P304
P356
10.1056/NEJMSA030954
P407
P577
2003-12-01T00:00:00Z